These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17055272)

  • 41. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
    Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
    Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Augeri DJ; Robl JA; Betebenner DA; Magnin DR; Khanna A; Robertson JG; Wang A; Simpkins LM; Taunk P; Huang Q; Han SP; Abboa-Offei B; Cap M; Xin L; Tao L; Tozzo E; Welzel GE; Egan DM; Marcinkeviciene J; Chang SY; Biller SA; Kirby MS; Parker RA; Hamann LG
    J Med Chem; 2005 Jul; 48(15):5025-37. PubMed ID: 16033281
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Pei Z; Li X; von Geldern TW; Madar DJ; Longenecker K; Yong H; Lubben TH; Stewart KD; Zinker BA; Backes BJ; Judd AS; Mulhern M; Ballaron SJ; Stashko MA; Mika AK; Beno DW; Reinhart GA; Fryer RM; Preusser LC; Kempf-Grote AJ; Sham HL; Trevillyan JM
    J Med Chem; 2006 Nov; 49(22):6439-42. PubMed ID: 17064063
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis.
    Nishioka T; Shinohara M; Tanimoto N; Kumagai C; Hashimoto K
    Dermatology; 2012; 224(1):20-1. PubMed ID: 22056790
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.
    Villhauer EB; Brinkman JA; Naderi GB; Burkey BF; Dunning BE; Prasad K; Mangold BL; Russell ME; Hughes TE
    J Med Chem; 2003 Jun; 46(13):2774-89. PubMed ID: 12801240
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel trans-2-aryl-cyclopropylamine analogues as potent and selective dipeptidyl peptidase IV inhibitors.
    Tsai TY; Hsu T; Chen CT; Cheng JH; Yeh TK; Chen X; Huang CY; Chang CN; Yeh KC; Hsieh SH; Chien CH; Chang YW; Huang CH; Huang YW; Huang CL; Wu SH; Wang MH; Lu CT; Chao YS; Jiaang WT
    Bioorg Med Chem; 2009 Mar; 17(6):2388-99. PubMed ID: 19261480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 4-arylcyclohexylalanine analogs as potent, selective, and orally active inhibitors of dipeptidyl peptidase IV.
    Kaelin DE; Smenton AL; Eiermann GJ; He H; Leiting B; Lyons KA; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE; Duffy JL
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5806-11. PubMed ID: 17851076
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine.
    Al-masri IM; Mohammad MK; Tahaa MO
    J Enzyme Inhib Med Chem; 2009 Oct; 24(5):1061-6. PubMed ID: 19640223
    [TBL] [Abstract][Full Text] [Related]  

  • 49. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
    Thomas L; Eckhardt M; Langkopf E; Tadayyon M; Himmelsbach F; Mark M
    J Pharmacol Exp Ther; 2008 Apr; 325(1):175-82. PubMed ID: 18223196
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin.
    Biftu T; Scapin G; Singh S; Feng D; Becker JW; Eiermann G; He H; Lyons K; Patel S; Petrov A; Sinha-Roy R; Zhang B; Wu J; Zhang X; Doss GA; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3384-7. PubMed ID: 17433672
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The design of potent and selective inhibitors of DPP-4: optimization of ADME properties by amide replacements.
    Nordhoff S; Bulat S; Cerezo-Gálvez S; Hill O; Hoffmann-Enger B; López-Canet M; Rosenbaum C; Rummey C; Thiemann M; Matassa VG; Edwards PJ; Feurer A
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6340-5. PubMed ID: 19833514
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.
    Beconi MG; Reed JR; Teffera Y; Xia YQ; Kochansky CJ; Liu DQ; Xu S; Elmore CS; Ciccotto S; Hora DF; Stearns RA; Vincent SH
    Drug Metab Dispos; 2007 Apr; 35(4):525-32. PubMed ID: 17220241
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Yoshida T; Akahoshi F; Sakashita H; Kitajima H; Nakamura M; Sonda S; Takeuchi M; Tanaka Y; Ueda N; Sekiguchi S; Ishige T; Shima K; Nabeno M; Abe Y; Anabuki J; Soejima A; Yoshida K; Takashina Y; Ishii S; Kiuchi S; Fukuda S; Tsutsumiuchi R; Kosaka K; Murozono T; Nakamaru Y; Utsumi H; Masutomi N; Kishida H; Miyaguchi I; Hayashi Y
    Bioorg Med Chem; 2012 Oct; 20(19):5705-19. PubMed ID: 22959556
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug evaluation: PSN-9301, a short-acting inhibitor of dipeptidyl peptidase IV.
    Epstein BJ
    Curr Opin Investig Drugs; 2007 Apr; 8(4):331-7. PubMed ID: 17458184
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure.
    Focosi D; Kast RE; Metelli MR; Benedetti E; Galimberti S; Papineschi F; Petrini M
    Leuk Res; 2009 Jan; 33(1):178-81. PubMed ID: 18513794
    [No Abstract]   [Full Text] [Related]  

  • 56. Discovery of non-covalent dipeptidyl peptidase IV inhibitors which induce a conformational change in the active site.
    Sheehan SM; Mest HJ; Watson BM; Klimkowski VJ; Timm DE; Cauvin A; Parsons SH; Shi Q; Canada EJ; Wiley MR; Ruehter G; Evers B; Petersen S; Blaszczak LC; Pulley SR; Margolis BJ; Wishart GN; Renson B; Hankotius D; Mohr M; Zechel JC; Michael Kalbfleisch J; Dingess-Hammond EA; Boelke A; Weichert AG
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1765-8. PubMed ID: 17239592
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Sitagliptin].
    Taéron C
    Rev Infirm; 2008 Oct; (144):46-8. PubMed ID: 19009789
    [No Abstract]   [Full Text] [Related]  

  • 58. Sitagliptin.
    Drucker D; Easley C; Kirkpatrick P
    Nat Rev Drug Discov; 2007 Feb; 6(2):109-10. PubMed ID: 17342863
    [No Abstract]   [Full Text] [Related]  

  • 59. 4-aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV.
    Duffy JL; Kirk BA; Wang L; Eiermann GJ; He H; Leiting B; Lyons KA; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 May; 17(10):2879-85. PubMed ID: 17350841
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus.
    Rosenstock J; Zinman B
    Curr Opin Endocrinol Diabetes Obes; 2007 Apr; 14(2):98-107. PubMed ID: 17940427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.